Inova is a national leader in lung transplantation and lung disease
Inova Advanced Lung Disease and Transplant Program, located on the campus of nationally top-ranked Inova Fairfax Hospital, is recognized for excellence and innovation. Inova transplant surgeons and lung specialists offer new hope to individuals dealing with serious life-threatening lung disease that once was considered untreatable.
We have performed over 200 lung transplants over the last 10 years, and according to the most recent Scientific Registry for Transplant Recipients (SRTR) report, our one-month and one-year survival rates are statistically higher than expected. Inova Fairfax Hospital is one of just three programs in the United States to achieve this distinction.
Read and watch videos of our patients' stories
The DC area's first and only lung transplant program
Inova pioneered lung and lung-heart transplants in the Northern Virginia and Washington, DC, metro areas. The first lung transplant was performed at Inova Fairfax Hospital in 1991. Today Inova remains sole provider of the region's only lung transplant program, with patient survival statistics above the national average.
Specialized care for advanced lung disease
Inova's advanced lung disease clinics provide highly specialized evaluation and treatment for serious lung disease. Our clinical experts continually seek out and implement the latest treatment techniques. These advancements may delay or forestall the need for a lung transplant or offer treatment options to patients not eligible for transplantation.
Shared clinical expertise
Dr. Steven Nathan, medical director of the Inova Advanced Lung Disease and Transplant Program, is internationally recognized for his expertise in serious lung conditions. He is co-editor of a recently published book, Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide.
A partner in national research efforts
Inova Advanced Lung Disease and Transplant Program is actively participating in state-of-the-art research studies pursuing more effective treatment for lung conditions. Our prestigious collaboration with the National Institutes of Health will further help develop new therapies for pulmonary hypertension, serious asthma and other lung disease. Learn more about the current research
Learn more about our world-class program